Advanced in Lynch Syndrome

Dr. Autumn J. Mcree

Hematology Oncology
170 Manning Dr, Chapel Hill, 
Chapel Hill, NC 
Clinical Trials:Currently Recruiting for 2 Trials
Advanced in Lynch Syndrome
170 Manning Dr, Chapel Hill, 
Chapel Hill, NC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Autumn Mcree is a Hematologist Oncology provider in Chapel Hill, North Carolina. Dr. Mcree is rated as an Advanced provider by MediFind in the treatment of Lynch Syndrome. Her top areas of expertise are Gastrointestinal Stromal Tumor, Undifferentiated Pleomorphic Sarcoma, Mesenchymoma, and Cholangiocarcinoma (Bile Duct Cancer).

Her clinical research consists of co-authoring 35 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Licenses
Internal Medicine in NC
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

170 Manning Dr, Chapel Hill, Chapel Hill, NC 27514

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

Impact of Tumor and Stromal Subtypes on Efficacy of Neoadjuvant FOLFIRINOX in Subjects With Non-Metastatic Pancreatic Cancer
Impact of Tumor and Stromal Subtypes on Efficacy of Neoadjuvant FOLFIRINOX in Subjects With Non-Metastatic Pancreatic Cancer
Enrollment Status: Recruiting
Publish Date: October 10, 2025
Intervention Type: Drug
Study Drugs: Oxaliplatin, Leucovorin, Irinotecan hydrochloride, 5-FU
Study Phase: Phase 2
Ulixertinib (BVD-523) in Combination With Palbociclib in Patients With Advanced Solid Tumors With Expansion Cohort in Previously Treated Metastatic Pancreatic Cancer and Metastatic RAS-mutant and NF1-mutant (no BRAFV600 Mutations) Melanoma
Ulixertinib (BVD-523) in Combination With Palbociclib in Patients With Advanced Solid Tumors With Expansion Cohort in Previously Treated Metastatic Pancreatic Cancer and Metastatic RAS-mutant and NF1-mutant (no BRAFV600 Mutations) Melanoma
Enrollment Status: Recruiting
Publish Date: September 11, 2025
Intervention Type: Drug
Study Drugs: Ulixertinib, Palbociclib
Study Phase: Phase 1
Phase II Single-arm Study of the Combination of Palbociclib and Cetuximab in KRAS/NRAS/BRAF Wild-type Metastatic Colorectal Cancer
Phase II Single-arm Study of the Combination of Palbociclib and Cetuximab in KRAS/NRAS/BRAF Wild-type Metastatic Colorectal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 22, 2025
Intervention Type: Drug
Study Drugs: Cetuximab, Palbociclib
Study Phase: Phase 2
Phase II Multicenter Trial of Panitumumab, Nivolumab, and Ipilimumab for KRAS/NRAS/BRAF Wild-type MSS Refractory Metastatic Colorectal Adenocarcinoma
Phase II Multicenter Trial of Panitumumab, Nivolumab, and Ipilimumab for KRAS/NRAS/BRAF Wild-type MSS Refractory Metastatic Colorectal Adenocarcinoma
Enrollment Status: Completed
Publish Date: July 01, 2025
Intervention Type: Drug
Study Drugs: Panitumumab, Nivolumab, Ipilimumab
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Clinical Study Comparing the Efficacy and Safety of Tislelizumab (BGB-A317) Plus Platinum and Fluoropyrimidine Versus Placebo Plus Platinum and Fluoropyrimidine as First-Line Treatment in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Clinical Study Comparing the Efficacy and Safety of Tislelizumab (BGB-A317) Plus Platinum and Fluoropyrimidine Versus Placebo Plus Platinum and Fluoropyrimidine as First-Line Treatment in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Enrollment Status: Completed
Publish Date: February 14, 2025
Intervention Type: Drug
Study Phase: Phase 3
Phase II Trial of ERK Inhibition Alone and in Combination With Autophagy Inhibition in Patients With Metastatic Pancreatic Cancer
Phase II Trial of ERK Inhibition Alone and in Combination With Autophagy Inhibition in Patients With Metastatic Pancreatic Cancer
Enrollment Status: Completed
Publish Date: February 12, 2025
Intervention Type: Drug
Study Drugs: Hydroxychloroquine Sulfate, LY3214996
Study Phase: Phase 2
A Single Arm, Multi-center Phase 2 Trial of mFOLFOX6 + Trastuzumab + Avelumab in First-line, Metastatic, HER2-amplified Gastric and Esophageal Adenocarcinomas
A Single Arm, Multi-center Phase 2 Trial of mFOLFOX6 + Trastuzumab + Avelumab in First-line, Metastatic, HER2-amplified Gastric and Esophageal Adenocarcinomas
Enrollment Status: Completed
Publish Date: December 19, 2023
Intervention Type: Drug
Study Drugs: Oxaliplatin, Leucovorin, 5 fluorouracil, Trastuzumab, Avelumab
Study Phase: Phase 2
Quantification and Characterization of Circulating Tumor Cells in Solid Tumors
Quantification and Characterization of Circulating Tumor Cells in Solid Tumors
Enrollment Status: Completed
Publish Date: September 28, 2022
Intervention Type: Other
An Open Label Randomized Phase I/II Trial of MLN0128 Compared to Sorafenib in Patients With Advanced or Metastatic Hepatocellular Carcinoma: Big Ten Cancer Research Consortium BTCRC-GI13-002
An Open Label Randomized Phase I/II Trial of MLN0128 Compared to Sorafenib in Patients With Advanced or Metastatic Hepatocellular Carcinoma: Big Ten Cancer Research Consortium BTCRC-GI13-002
Enrollment Status: Terminated
Publish Date: July 26, 2022
Intervention Type: Drug
Study Drugs: MLN0128, MLN0128 (RP2D), Sorafenib
Study Phase: Phase 1/Phase 2
A Multi-center Study of hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse Post Definitive Surgery and Standard Therapy
A Multi-center Study of hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse Post Definitive Surgery and Standard Therapy
Enrollment Status: Completed
Publish Date: November 19, 2018
Intervention Type: Biological
Study Phase: Phase 1
View 8 Less Clinical Trials

35 Total Publications

Phase II single-arm study of palbociclib and cetuximab in anti-EGFR naïve patients with KRAS/NRAS/BRAF wild-type, metastatic colorectal cancer.
Phase II single-arm study of palbociclib and cetuximab in anti-EGFR naïve patients with KRAS/NRAS/BRAF wild-type, metastatic colorectal cancer.
Journal: The oncologist
Published: July 15, 2025
Similar Doctors
Distinguished in Lynch Syndrome
Dr. Gary B. Sherrill
Hematology Oncology | Oncology | Hematology
Distinguished in Lynch Syndrome
Dr. Gary B. Sherrill
Hematology Oncology | Oncology | Hematology

The Moses H Cone Memorial Hospital Operating Corporation

3518 Drawbridge Pkwy, Suite 210, 
Greensboro, NC 
 (48.4 miles away)
336-890-3100
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Gary Sherrill is a Hematologist Oncology specialist and an Oncologist in Greensboro, North Carolina. Dr. Sherrill is rated as a Distinguished provider by MediFind in the treatment of Lynch Syndrome. His top areas of expertise are Colorectal Cancer, Familial Colorectal Cancer, Lynch Syndrome, and Familial Pancreatic Cancer. Dr. Sherrill is currently accepting new patients.

Diane Reidy
Distinguished in Lynch Syndrome
Dr. Diane Reidy
Hematology Oncology | Hematology | Oncology
Distinguished in Lynch Syndrome
Dr. Diane Reidy
Hematology Oncology | Hematology | Oncology

Duke Cancer Center

20 Duke Medicine Cir, 
Durham, NC 
 (9.5 miles away)
919-681-6900
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Diane Reidy is a Hematologist Oncology specialist and a Hematologist in Durham, North Carolina. Dr. Reidy is rated as an Elite provider by MediFind in the treatment of Lynch Syndrome. Her top areas of expertise are Neuroendocrine Tumor, Pancreatic Islet Cell Tumor, Pancreatic Cancer, Pancreaticoduodenectomy, and Liver Embolization.

Advanced in Lynch Syndrome
Dr. S D. David
Hematology Oncology | Hematology | Oncology
Advanced in Lynch Syndrome
Dr. S D. David
Hematology Oncology | Hematology | Oncology

Duke Cancer Center

20 Duke Medicine Cir, 
Durham, NC 
 (9.5 miles away)
919-681-6900
Experience:
25+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

S David is a Hematologist Oncology specialist and a Hematologist in Durham, North Carolina. Dr. David has been practicing medicine for over 25 years and is rated as a Distinguished provider by MediFind in the treatment of Lynch Syndrome. His top areas of expertise are Colorectal Cancer, Familial Colorectal Cancer, Gastroesophageal Junction Cancer, and Familial Pancreatic Cancer.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mcree's expertise for a condition
ConditionClose
    View All 8 Advanced Conditions
    View All 8 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile